Medesis Pharma S.A.

Equities

ALMDP

FR0010844464

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 05:23:02 2024-05-10 am EDT			5-day change	1st Jan Change
1.39 ^EUR	-1.42%		+15.83%	+60.14%

2023	Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	MEDESIS : Invest Securities confirms its recommendation	CF

Medesis Pharma: selected for the Prix Galien USA

August 04, 2023 at 06:36 am EDT

Medesis Pharma announced today that it has been nominated for the Prix Galien USA Award 2023 in the 'Best Startup' category by the Fondation Galien, the world's leading institution dedicated to honoring innovation in the life sciences, in partnership with Business France.

The Prix Galien was created in France in 1970 to reward innovative treatments and technologies that improve human health.

The winners will be announced at the Prix Galien USA Forum on October 26, 2023, at the Alexandria Center for Life Science in New York.

Copyright (c) 2023 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ALEXANDRIA GROUP OYJ	7.9 EUR	+3.27%	+0.64%	87.19M
	MEDESIS PHARMA S.A.	1.39 EUR	-1.42%	+15.83%	6.63M

Latest news about Medesis Pharma S.A.

Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-27	CI
MEDESIS : Invest Securities confirms its recommendation	23-10-06	CF
Medesis Pharma: selected for the Prix Galien USA	23-08-04	CF
MEDESIS : Invest Securities maintains its recommendation	23-07-12	CF
MEDESIS : Invest Securities confirms its recommendation	23-07-07	CF
Global markets live: Gamestop, Lucid, Meta Platforms, Vodafone, Nestlé...	23-06-08
Global markets live: Shell, Netflix, Nike, Ocado, Tesla...	23-03-31
Global markets live: Blackberry, Meta Platforms, Rivian, GM...	23-03-07
Medesis Pharma Soars 16% On New Grant For Investigational Huntington's Disease Drug	22-07-20	MT
Medesis Pharma Up 65% After Asking Funds For Nuclear Contamination Drugs	22-04-05	MT
Medesis Pharma Publishes an Information Note on the Three Future Drugs in Development for the Protection of Large Populations Contaminated After A Civil or Military Nuclear Accident	22-04-05	CI
Medesis Pharma Wins COVID-19 Drug Trial Approval In Brazil	21-11-22	MT
Global markets live: Ford, Walmart, Apple, Volkswagen, Tesla...	21-09-02
Global markets live: Nvidia, Microsoft, Dell, Apple, Uber...	21-08-27
Medesis Pharma S.A.(ENXTPA:ALMDP) added to Next Biotech Index	21-02-15	CI
Medesis Pharma S.A. has completed an IPO in the amount of €7.350317 million.	21-02-09	CI
Medesis Pharma S.A. has filed an IPO in the amount of €7.350317 million.	21-01-26	CI
Medesis Pharma SA announced that it has received €0.04 million in funding	15-10-25	CI
Medesis Pharma SA announced that it expects to receive €1 million in funding.	15-09-17	CI

Chart Medesis Pharma S.A.

Duration

Period

More charts

Company Profile

Medesis Pharma S.A. is specialized in the research and development, based on a breakthrough technology (AONYS®) for the delivery of therapeutic molecules, of drugs to treat diseases for which there is no effective treatment. The company's portfolio includes a drug candidate used to optimize cancer radiotherapy, 2 drug candidates used in the treatment of neurodegenerative diseases (Alzheimer's disease and Huntington's disease) and 2 drug candidates used in the treatment of radioactive contamination following a civil or military nuclear accident (Plutonium decorporation and cesium decorporation).

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEDESIS PHARMA S.A.	+60.14%	6.63M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs